MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline

Merck (MRK) reported positive Phase III data for enlicitide decanoate, its oral PCSK9 inhibitor, demonstrating statistically significant LDL-C reduction, positioning it as a potential first-in-class oral therapy for hypercholesterolemia. This pipeline advancement is critical for Merck, which has nearly tripled its late-stage pipeline since 2021, aiming for approximately 20 new drug and vaccine launches to drive long-term growth as Keytruda's exclusivity approaches in 2028. Despite a 14.1% year-to-date share decline, the company's valuation appears attractive at 9.12x forward earnings, below the industry average.

Analysis

Merck is demonstrating significant progress in its strategy to build a robust post-Keytruda growth engine, underscored by positive top-line data from the pivotal Phase III study of its oral PCSK9 inhibitor, enlicitide decanoate. The drug met all primary and secondary endpoints, showing a statistically significant reduction in LDL-C, which positions it to potentially become the first-in-class oral therapy in a market currently dominated by injectables from Amgen and Regeneron/Sanofi. This pipeline advancement is part of a broader, aggressive expansion that has nearly tripled Merck's Phase III pipeline since 2021, with plans for approximately 20 new launches. This strategy is already bearing fruit with strong initial launches of the vaccine Capvaxive and the PAH drug Winrevair, alongside the recent U.S. approval of the RSV antibody Enflonsia. Despite these positive fundamental developments, Merck's stock has underperformed significantly, declining 14.1% year-to-date compared to a 0.5% dip for the industry. This has resulted in a valuation that appears attractive, with the stock trading at a forward P/E of 9.12, well below the industry average of 14.78 and its own five-year mean of 12.73. However, competition remains a key factor, as AstraZeneca is also developing a competing oral PCSK9 inhibitor, AZD0780, which has shown a favorable safety profile in mid-stage studies.

Key Decisions for Investors

• Given the stock's 14.1% year-to-date underperformance and a forward P/E of 9.12x, which is well below industry and historical averages, the current valuation may present a compelling entry point for value-oriented investors who are bullish on the company's pipeline execution.
• Investors should closely monitor the commercial trajectory of newly launched products like Capvaxive and Winrevair, as their success provides tangible evidence of Merck's ability to de-risk its revenue base ahead of the 2028 Keytruda patent expiration.
• While the oral format of enlicitide decanoate is a key potential differentiator, it is crucial to track the clinical progress of AstraZeneca's rival oral PCSK9 inhibitor, AZD0780, as its development represents a primary competitive risk to Merck's future market share in this category.